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Abstract
Background: Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours.
Objective: Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular
carcinoma (HCC) treated with sorafenib.
Methods: We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with
available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory,
treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an
L3 section CT image.
Results: Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was
significantly higher in the sarcopenic group (SG) (66 years (31–87) versus 72 years (30–84), p¼ 0.04], with no difference in
other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26–50) versus 61
(95% CI 47–77) weeks (p¼ 0,01)) and shorter time on treatment (12.3 (95% CI 8–19) versus 25.9 (95% CI 15–33) weeks
(p¼ 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p¼ 0.03) and reduced time
on treatment (p¼ 0.001).
Conclusion: Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and
reduced duration of oral chemotherapy.
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Key summary
. Sarcopenia has been associated with poor outcomes in patients with cirrhosis and hepatocellular carcin-
oma (HCC), and with reduced tolerance to chemotherapy.
. Our study indicates that sarcopenia is present in almost half of cirrhotic patients with advanced HCC
selected to undergo sorafenib treatment.
. Sarcopenia was found to be independently associated with a twofold risk of mortality and reduced
sorafenib treatment duration.
. Baseline measurement of sarcopenia could improve prediction of mortality in patients with advanced
HCC.
Introduction
Hepatocellular carcinoma (HCC) is the third cause of
cancer related deaths, with rising incidence worldwide,
with nearly 750,000 new cases per year.1
Epidemiological data suggest that the incidence of
HCC is still similar to the death rate, and thus almost
all patients who are diagnosed with HCC will die
because of it.1 In developed countries, HCC predomin-
antly aﬀects the elderly, and is diagnosed at an
advanced stage (Barcelona Clinic Liver Cancer
(BCLC-C)) in up to 40% of all patients.2 At this
stage, the only approved treatment in Italy is sorafenib
(Nexavar, Bayer), an orally administered multikinase
inhibitor shown to improve survival, but burdened by
relatively high costs and toxicity rates, limiting patients’
chances of receiving full dose treatment and hindering
their quality of life.3
Therefore, the search for prognostic tools able to
stratify risk, predict toxicity and allow for therapy tai-
loring for each patient is of major clinical interest.4
The condition of reduced muscle mass, deﬁned as
sarcopenia,5,6 has been identiﬁed as an independent
predictor of reduced survival, tolerance to chemother-
apy and higher rates of toxicity in patients with diﬀer-
ent neoplasias.7–10 In the research setting, imaging
techniques such as computed tomography (CT) scan-
ning are considered the gold standard for estimating
muscle mass.6 In the ﬁeld of hepatology, sarcopenia
has been linked to reduced survival rates in diﬀerent
therapeutic settings such as liver transplantation, hepa-
tic resection and intra-arterial treatments for HCC.11–15
Its presence has also been associated with increased
toxicity in patients with HCC treated with sorafenib16
and reduced survival, but the few data available come
mainly from oriental series, where ethnic and anthropo-
metric diﬀerences limit reproducibility in a Western set-
ting.17–19 Only one Western study is available, with a
limited number of patients treated with various tyrosine
kinase inhibitors.20
The aim of the present study was to identify the
prevalence and inﬂuence of sarcopenia in a homoge-
neous population of European Caucasian patients
with advanced HCC undergoing sorafenib therapy.
We aimed to evaluate the inﬂuence of sarcopenia on
patients’ survival, as well as on the duration and toler-
ance of sorafenib treatment.
Materials and methods
Study design
This is a multicentre, retrospective study to assess the
added value of sarcopenia evaluation in patients with
advanced HCC and patients with an intermediate HCC
who were not eligible for or failed ablative therapies,
treated with sorafenib according to international guide-
lines.2 Patients were followed and included in four dif-
ferent units in three hospital centres from 2008 to 2016.
Patients and data collection
All patients with advanced HCC, i.e. classiﬁed as
BCLC stage C and those with a BCLC-B stage who
were unﬁt to any or failed to respond to locoregional
therapies,2 were enrolled. HCC was diagnosed by the
criteria of the American Association for the Study
of Liver Disease21 and staged by abdominal dynamic
contrast-enhanced CT scan or gadolinium-enhanced
magnetic resonance imaging (MRI). Each patient
underwent also chest X-ray/CT scan and bone scanning
as requested by the attending physicians.
The main inclusion criteria were those speciﬁed by
the Italian Medicines Agency (AIFA) and the availabil-
ity of an abdominal CT scan within 1 month before the
start of sorafenib treatment. We analysed gender, age,
pre-treatment anthropometric features, laboratory ﬁnd-
ings (including serum albumin, creatinine, international
normality ratio (INR) and alpha-fetoprotein (AFP)),
dry weight body mass index (BMI), macrovascular
invasion and extra-hepatic spread. Cirrhosis, diagnosed
either by histology or clinically, was graded according
to the Child–Pugh and Model for End-stage Liver
Disease (MELD) scores as a measures of liver impair-
ment.22,23 Performance status (PS) was scored accord-
ing to the Eastern Cooperative Oncology Group
(ECOG).24 All data were obtained within 1 month
before the start of sorafenib treatment. Follow-up
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was ended at patients’ death, last visit or on 10
December 2016.
After initial data collection, all patients were given an
identiﬁcation number to guarantee anonymity and
information was entered in a dedicated database for
statistical analysis. All patients gave informed consent
for the use of clinical, laboratory and radiological data
at the time of the ﬁrst examination. The study protocol
conforms to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by local the
institutional review board (Comitato EticoMilano Area
2, Universita` degli Studi di Milano, 3 December 2017).
Image analysis and treatment modality
CT scans were obtained routinely at baseline for
tumour staging purposes within 1 month prior to initi-
ation of sorafenib treatment and used to determine the
skeletal muscle index (SMI). A transverse image at the
level of the third lumbar vertebrae (L3) was selected
from each scan. Muscles at this level include psoas,
erector spinae, quadratus lumborum, transversus abdo-
minis, external and internal obliques, and the rectus
abdominis.10,13,25 Images were analysed with
SliceOmatic V 5.0 software (Tomovision, Montreal,
Quebec, Canada), which enables speciﬁc tissue selection
by using previously determined Hounsﬁeld units (HU).
Skeletal muscle is selected and quantiﬁed by thresholds
between –29 to þ150 HU.26 These speciﬁc thresholds
permit evaluation of skeletal muscle regardless of asci-
tes in patients with cirrhosis, excluding muscular fat
inﬁltration in the selected section. All CT images were
analysed by two trained observers (GA and PB). Cross-
sectional areas were calculated and normalized for
height (cm2/m2) as reported elsewhere.27 The MRI ima-
ging data were excluded to avoid methodological het-
erogeneity. L3 SMI was expressed in cm2/m2. L3 SMI
was considered to be indicative of sarcopenia if
53 cm2/m2 for male patients with a BMI 25 and
43 cm2/m2 in male patients with a BMI <25
and 41 cm2/m2 for women, independently of BMI.9
Sorafenib treatment was administered according to
guidelines. Therapy was discontinued whenever the
patient developed unacceptable toxicity, when radio-
logical or symptomatic progression of HCC occurred,
or by investigator’s judgment of the patient being
unlikely to beneEt from further treatment with sorafe-
nib. Tumour progression was deEned either radio-
logically by modiEed response evaluation criteria in
solid tumours (mRECIST)28 or clinically in terms
of worsening of PS or onset of symptoms unrelated
to liver failure.29 Another reason for treatment discon-
tinuation was unacceptable treatment toxicity,
i.e. grade 2–4 adverse events (AEs) not responding
to dose reductions and/or temporary interruption
of treatment as suggested by the manufacturer.24,30
Toxicity was assessed in all patients who received
at least one dose of sorafenib; AEs were graded accord-
ing to the National Cancer Institute’s Common
Terminology Criteria (version 3.0).31
Statistical analysis
Patients were divided in two groups according to the
presence of sarcopenia and characteristics of the two
groups were then compared. Continuous data were
reported as mean  SD or as median (range) and com-
pared using a Student’s t-test or Mann–Whitney test
as appropriate. Categorical variables were expressed
as number (percentage) and compared using the 2
test with Fisher’s exact test, with Yates’ correction as
appropriate. Survival curves were estimated using the
Kaplan–Meier method and compared using the log-
rank test. Overall survival (OS) time was deﬁned as
the period between treatment start and patient death,
and the time on treatment was intended as time from
treatment beginning to its end. Univariate analyses
were performed using Cox’s proposal hazards
model and hazard ratios (HRs) of independent predict-
ive factors were obtained. The variables signiﬁcantly
associated with endpoints in univariate analysis
were entered in a sex- and age-adjusted multivariate
model. All p-values were two sided and the level
of signiﬁcance was set at p< 0.05. Results are
reported as HR and 95% conﬁdence interval (CI). All
statistical analyses were carried out on MedCalc 12.5
statistical software. Data are expressed as percentage
(number/total) median (range) for demographic and
laboratory data in tables and text unless otherwise
indicated.
Results
Clinical and biochemical characteristics of
advanced HCC patients treated with sorafenib
Of the 119 initial patients selected for the study,
15 patients were excluded since they had only a baseline
MRI available, 4 were excluded since CT imaging
and/or required clinical/laboratory data were missing,
and 4 patients were excluded since treatment was
administered in an oﬀ-label schedule. Therefore,
96 Caucasian patients treated with sorafenib were
included in the ﬁnal analysis: 75 were men (78%),
with a median age of 69 years (30-87); 21 patients
were female (22%), all post-menopausal. The most
prevalent cause of cirrhosis was chronic viral infection
(hepatitis C virus and hepatitis B virus, 62%), while
alcohol abuse ranked second (17%). Other baseline
characteristics are summarized in Table 1.
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Lumbar SMI and sarcopenia distribution
At baseline, the median value of the L3 SMI was
47.2 cm2/m2 (range 23.4–70). The median SMI L3
value was 49.7 cm2/m2 (range 33.3–70) in males and
36 cm2/m2 (range 23.4–49.8) in females: 47 (49%)
patients were deﬁned sarcopenic. Inter-observer con-
cordance on L3 SMI values was >95%.
Sarcopenia was signiﬁcantly more prevalent in
women (91% versus 37%, p¼< 0.0001) and in older
patients (66 (range 31–87) versus 72 years (range 30–
84), p¼ 0.04]. Grades of hepatic dysfunction expressed
by the Child–Pugh and MELD scores were not signiﬁ-
cantly diﬀerent in the two groups, as well as serum
albumin, creatinine, sodium, total bilirubin, INR and
AFP (data available for 84 patients). Data describing
the diﬀerences between the two groups are detailed in
Table 2. In particular, median BMI values were not
diﬀerent (24.6 (range 20.8–38.7) versus 24.4 (range
16.2–30), p¼not signiﬁcant). Among the 58 patients
with BMI< 25, 28 (48%) were sarcopenic, while
among the 38 patients with a BMI 25, 50% were
sarcopenic (p ¼ not signiﬁcant).
Factors influencing survival in advanced HCC
patients treated with sorafenib
Overall survival in our cohort was 50 (3.1–298.1) weeks.
According to the Kaplan–Meier method, median OS
was signiﬁcantly shorter among sarcopenic patients
(63 versus 32 weeks, HR 1.69, p¼ 0.02) (Figure 1).
By univariate Cox analysis, factors associated with
an increased mortality after sorafenib treatment were
bilirubin level (p¼ 0.02; HR 1.75) (cut-oﬀ 1.4mg/dL),
vascular invasion (p¼ 0.03; HR 1.76), MELD (p¼ 0.01;
HR 1.08) and sarcopenia deﬁned by L3 SMI (p¼ 0.01;
HR 1.71), while male gender, age, BMI, presence of
ascites, INR, AFP, creatinine, albumin, sodium and
Child–Pugh score were not associated with a higher
mortality rate. In sex- and age-adjusted multivariate
analysis using a Cox regression model (bilirubin was
not entered to avoid colinearity with MELD score),
the only independent factor signiﬁcantly associated
with an increased mortality was sarcopenia (p¼ 0.03;
HR 1.63). Univariate and multivariate analyses for
OS are shown in Table 3.
Factors influencing time on treatment and
sorafenib tolerance
Overall, in our cohort, time on treatment was 19.2 (1.1–
134.2) weeks. By Kaplan–Meier analysis, time on treat-
ment was signiﬁcantly shorter among sarcopenic
patients (25.8 versus 12.3 weeks, HR 1.75, p¼ 0.0044)
(Figure 2). All patients at the end of follow-up had
Table 1. Baseline clinical and biochemical characteristics of
96 patients with advanced hepatocellular carcinoma treated with
sorafenib.
Characteristics N ¼ 96
Men, number 75 (78%)
Age, yearsa 69 (30–87)
Aetiology, number
HCV 46 (48%)
HBV 13 (14%)
Alcohol 16 (17%)
NASH 11 (11%)
Other 10 (10%)
BMI, kg/m2a
Overall 24.5 (16.2–38.7)
Male 24.7 (19.6–38.7)
Female 22.7 (16.2–30)
<25 kg/m2, number 58 (60%)
>25 kg/m2, number 38 (40%)
INR 1.10 (0.88–2.6)
Albumin, g/dLa 3.7 (2.7–5.0)
Bilirubin, mg/dLa 0.94 (0.3–5.0)
Creatinine, mg/dLa 0.8 (0.4–1.7)
Alpha-fetoprotein, ng/mla 68 (1–26941)
Encephalopathy, number 0
Ascites, number 20 (21%)
Child–Pugh score, number
A 80 (83%)
B 16 (17%)
MELD score 8 (6–21)
Tumour vascular invasion 18 (19%)
Metastases, number 20 (21%)
ECOG PS, number
0 36 (37.5%)
1 36 (37.5%)
2 24 (25%)
BCLC stage, number
B 22 (23%)
C 74 (77%)
L3 SMI, cm2/m2a
Overall 47.2 (23.4–70)
Male 49.7 (33.3–70)
Female 36 (23.4–49.8)
Sarcopenia, number 47 (49%)
HCV: hepatitis C virus; HBV: hepatitis B virus; NASH: non-alcoholic steato-
hepatitis; BMI: body mass index; INR: international normalized ratio; MELD:
Model for End-stage Liver Disease; ECOG PS: Eastern Cooperative Oncology
Group performance status; BCLC: Barcelona Clinic Liver Cancer; L3 SMI:
Muscle Skeletal Index at the third lumbar vertebra.
aMedian (range).
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discontinued sorafenib: 47 (49%) for disease progres-
sion, 42 (44%) for toxicity and 7 (7%) for liver decom-
pensation. Sarcopenic patients signiﬁcantly suﬀered
sorafenib-related toxicity (AEs grade 3 and 4) as com-
pared to non-sarcopenic patients (62% versus 40%,
p¼ 0.04). Information concerning drug dose reduction
was available for 55 patients. When available, there was
no diﬀerence in dose reduction between sarcopenic and
non-sarcopenic patients (43% versus 37%, p¼not
signiﬁcant).
By univariate Cox analysis, factors signiﬁcantly
associated with a reduced time on treatment were bili-
rubin level (p¼ 0.001; HR 1.66), vascular invasion
(p¼ 0.04; HR 1.69), Child–Pugh score (p¼ 0.007; HR
1.43), creatinine (p¼ 0.04; HR 2.56), albumin (p¼ 0.03;
HR 1.62), MELD (p¼ 0.0009; HR 1.13) and sarcopenia
deﬁned by L3 SMI (p¼ 0.005; HR 1.82). Male gender,
age, BMI, presence of ascites, INR, AFP and sodium
were not associated with reduced time on treatment.
In sex- and age-adjusted multivariate analysis using
the Cox regression model (albumin, bilirubin and
creatinine were not entered to avoid colinearity with
Child–Pugh and MELD scores), sarcopenia
(p¼ 0.001; HR 1.72), MELD (p¼ 0.03; HR 1.08),
Child–Pugh (p¼ 0.04; HR 1.34) and vascular inva-
sion (p¼ 0.04; HR 1.73) were shown to be independ-
ent factors signiﬁcantly associated with a reduced
time on treatment. Detailed univariate and multi-
variate analyses for time on treatment are shown in
Table 4.
Table 2. Comparison of clinical and biochemical characteristics among sarcopenic and non-sarcopenic
patients.
Characteristics
Sarcopenic
number 47 (49%)
Non-sarcopenic
number 49 (51%) p-value
Male 28 (60%) 47 (96%) <0.0001a
Age, yearsb 72 (30–84) 66 (31–87) 0.04c
L3 SMI, cm2/m2b 38.94 (23.42–52.62) 52.85 (43.1–70.1) <0.0001c
BMI, kg/m2b 24.4 (16.2–30) 24.6 (20.8–38.7) 0.07c
Albumin, g/dLb 3.6 (2.7–4.3) 3.8 (2.7–5.0) 0.2c
Bilirubin, mg/dLb 1.05 (0.3–5.0) 0.9 (0.3–3.4) 0.5c
Creatinine, mg/dLb 0.8 (0.4–2.3) 0.8 (0.55–1.7) 0.7c
Alpha-fetoprotein, ng/ml 47 (1–14662) 61 (1–26941) 0.2c
Aetiology 0.5
HCV 18 (38%) 28 (57%)
HBV 9 (19%) 4 (8%)
Alcohol 11 (23%) 5 (10%)
NASH 5 (11%) 8 (17%)
Other 4 (9%) 4 (8%)
Ascites, number 11 (23%) 8 (16%) 0.4a
Child–Pugh score A, number 37 (79%) 43 (88%) 0.1c
MELD scoreb 9 (6–21) 10 (6–15) 0.4c
BCLC, number 0.7c
B 11 (23%) 11 (22%)
C 36 (77%) 38 (78%)
ECOG PS (0/1/2) 17/20/10 19/16/14 0.2c
Toxicity, number 29 (62) 20 (40) 0.04a
Overall survival, weeksb 32 (3.1–171.2) 63 (6.5–298.1) 0.02c
Time on treatment,
weeksb
12.3 (1.1–103.1) 25.8 (2–134.2) 0.01c
L3 SMI: Muscle Skeletal Index at 3rd lumbar vertebra; BMI: body mass index; INR: international normalized ratio; HCV:
hepatitis C virus; HBV: Hepatitis B virus; NASH: non-alcoholic liver disease; MELD: Model for End-stage Liver Disease; BCLC:
Barcelona Clinic Liver Cancer; ECOG PS: Eastern Cooperative Oncology Group performance status.
aFisher’s exact test.
bMedian (range).
cMann–Whitney test.
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Discussion
To the best of our knowledge, this is the largest multi-
centre study addressing the relationship between
sarcopenia and survival in a homogeneous cohort of
European Caucasian cirrhotic patients with advanced
HCC treated with sorafenib. Our study indicates that
sarcopenia is present in almost half of cirrhotic patients
Table 3. Univariate and multivariate analysis of risk factors for overall survival of hepatocellular carcinoma patients treated
with sorafenib by the Cox proportional hazards model.
Univariate Multivariatea
Characteristics HR (95% CI) p-value HR (95% CI) p-value
Age (years) 0.98 (0.96–1.01) 0.36
Albumin (mg/dL) 0.71 (0.45–1.14) 0.16
Ascites 0.90 (0.53–1.54) 0.72
Sex (male) 1.04 (0.62–1.75) 0.86
Creatinine (mg/dL) 1.78 (0.74–4.25) 0.2
Sarcopenia 1.71 (1.12–2.71) 0.01 1.63 (1.05–2.53) 0.03
INR 1.17 (0.6–2.25) 0.63
Vascular invasion 1.76 (1.03–3.00) 0.03 1.65 (0.96–2.84) 0.07
Bilirubin (mg/dL) 1.75 (1.22–2.51) 0.02
AFP (ng/ml) 1.12 (0.78–2.11) 0.44
MELD score 1.08 (1.01–1.15) 0.01 1.01 (0.93–1.10) 0.13
Metastasis 0.86 (0.51–1.43) 0.57
ECOG PS 1.19 (0.93–1.52) 0.16
BMI (kg/m2) 1.00 (0.94–1.06) 0.9
Child–Pugh score 1.32 (0.98–1.78) 0.07
HR: hazard ratio; CI: confidence interval; INR: international normalized ratio; AFP: alpha-fetoprotein; MELD: Model for End-stage Liver
Disease; ECOG PS: Eastern Cooperative Oncology Group performance status; BMI: body mass index.
aBilirubin was not included in the multivariate analysis to avoid colinearity, since it was included in the MELD score.
100
80
60
40
20
0
0 10 20 30 40 50
Time (weeks)
Number at risk
Group: Absent
49 46 39 37 34 29 26 19 15 14 12
4471013192226374147
Group: Present
Su
rv
iva
l p
ro
ba
bi
lity
 (%
)
Overall survival
Sarcopenia
Absent
Present
p = 0.01
60 70 80 90 100
Figure 1. Kaplan Meier Curve for Overall Survival comparing sarcopenic and non sarcopenic patients.
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Figure 2. Kaplan Meier Curve for Sorafenib treatment duration comparing sarcopenic and non sarcopenic patients.
Table 4. Univariate and multivariate analysis of risk factors for time on treatment of hepatocellular carcinoma
patients treated with sorafenib by the Cox proportional hazards model.
Univariate Multivariatea
Characteristics HR (95% CI) p-value HR (95% CI) p-value
Age (years) 1.00 (0.98–1.02) 0.68
Albumin (mg/dL) 1.62 (1.4–1.95) 0.03
Sex (male) 1.06 (0.64–1.74) 0.81
MELD score 1.13 (1.05–1.21) 0.0009 1.08 (1.00–1.16) 0.03
Bilirubin 1.66 (1.22–2.26) 0.001
AFP (ng/ml) 1.09 (0.71–1.84) 0.31
INR 1.44 (0.58–3.58) 0.42
ECOG PS 1.06 (0.84–1.35) 0.58
Vascular invasion 1.69 (1.01–2.85) 0.04 1.73 (1.02–2.93) 0.04
Creatinine 2.56 (1.04–6.2) 0.04
BMI (kg/m2) 0.98 (0.93–1.04) 0.71
Child–Pugh score 1.43 (1.10–1.87) 0.007 1.34 (1.01–1.77) 0.04
Metastasis 0.87 (0.53–1.41) 0.57
Sarcopenia 1.82 (1.20–2.76) 0.005 1.72 (1.12–2.64) 0.001
Ascites 1.46 (0.88–2.44) 0.14
HR: hazard ratio; CI: confidence interval; INR: international normalized ratio; AFP: alpha-fetoprotein; MELD: Model for End-stage
Liver Disease; ECOG PS: Eastern Cooperative Oncology Group performance status; BMI: body mass index.
aBilirubin, creatinine and albumin were not included in the multivariate analysis to avoid colinearity, since they were included in
either the Child–Pugh or MELD scores.
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with advanced HCC selected to undergo sorafenib
treatment. In our cohort, sarcopenia was independently
associated with a twofold risk of mortality and reduced
treatment duration, and inclusion of its measurement at
baseline could be associated with an improvement
in the prediction of mortality in patients with
advanced HCC.
Available data demonstrate that sarcopenia is com-
monly observed among patients with cirrhosis and
associated with signiﬁcant morbidity and mortality,
contributing to reduced quality of life. Among cancer
patients, prevalence of pre-therapeutic sarcopenia was
found to be 38.6% in a recent comprehensive review of
32 studies.32
In our population of cirrhotic patients with
advanced HCC, the prevalence of sarcopenia, as
derived by a measurable and reproducible technique,
was even higher, probably due to the association of
advanced stage cancer and underlying liver disease.
This percentage is in line with those observed among
HCC cirrhotic patients and in our previous paper in
Caucasian patients with HCC using similar L3 SMI
thresholds.11,15 As expected, sarcopenia was linked to
gender and age. A paper from Japan previously
reported a higher prevalence of sarcopenia in patients
treated with sorafenib (close to 65%), probably linked
to diﬀerent thresholds chosen from Asian series pub-
lished in the literature, and as suggested by the authors,
could be unﬁt for Caucasian patients.17 At odds with
oriental data, sarcopenia was less represented in our
patients, further suggesting a role of ethnicity in inﬂu-
encing results in this setting.
Unexpectedly, sarcopenia was more prevalent in
female patients, a discordant result when compared to
most of the available literature. Our ﬁnding may be due
to the homogeneous composition of our cohort, which
was comprised exclusively of patients of Caucasian-
Mediterranean origin, again suggesting a possible role
of ethnicity in determining the development of sarcope-
nia, and to the generalized post-menopausal state of
our female patients, as it is well known that the pro-
tective eﬀect of oestrogens in counteracting sarcopenia
development is lost after menopause.33
Sarcopenia measurement can be obtained at margin-
ally increased costs from CT scans already available at
baseline for staging purposes, providing a further inde-
pendent prognostic index to plan appropriate patient
management. Furthermore, the dedicated software
used overcomes the intrinsic limits of bioimpedance
and anthropometric measurement, hampered by ele-
vated BMI and ascites.6,34,35 In addition, since the meas-
urements we performed were not limited to the psoas
only, but comprised all the muscles represented in the
transverse image selected, it maximized the opportunity
to obtain a representative sample of muscle mass.
Sarcopenic patients experienced more serious AEs
and remained on treatment for a shorter period of
time, which suggests that sarcopenia could assist in per-
formance status evaluation, normally applied to HCC
patients for staging and treatment allocation.2 The role
of reduced muscle mass in exposing patients to an
increased risk of developing sorafenib-related side
eﬀects has been reported in a previous study.16 Our
study, conducted in a larger and homogeneous sample
representative of advanced HCC, including diﬀerent
degrees of liver functional reserve and performance
status, conﬁrms and completes these ﬁndings.
An additional relevant ﬁnding of our study is that
sarcopenia was prevalent in 49% of overweight/obese
patients (BMI 25). This observation conﬁrms the
warning that sarcopenia is not exclusively to be
sought in patients with low BMI, strengthening the
importance and prevalence of sarcopenic obesity.10,11,15
Our data further contributes to the deﬁnition of the
role of sarcopenia as a possible predictor of reduced
survival and cancer treatment toxicity, as has been pre-
viously shown in other oncological settings.10 Accurate
measurement tools are also needed in HCC, and CT-
based technologies provide measurable and repeatable
muscle mass measurement. We believe that sarcopenia
assessment can certainly be an additional component in
the complex decision-making process surrounding
therapeutic choices in advance HCC.
The main limitation of our study is the retrospective
design, which cannot exclude selection bias, that was
nonetheless minimized by cross-referencing clinical and
radiological databases, and the unavailability of full
data regarding sorafenib initial dose and dose
reduction.
In conclusion, our data show that European
Caucasian cirrhotic patients with advanced HCC have
a high prevalence of sarcopenia, and that its measure-
ment by CT scan could be a readily available tool to
identify them, improving prognostic evaluation at min-
imally increased costs.
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